Aims The purpose of this study was to evaluate the effects of renal impairment on the single-dose pharmacokinetics of the antiepileptic felbamate. Methods Twelve subjects with three levels of renal dysfunction (creatinine clearance >30-80, >10-30 or 5-10 m min −1 ) and four controls with normal renal function (creatinine clearance >80 ml min −1 were studied). Plasma and urine samples were obtained for 144 h following administration of a single 1200 mg dose.
; patients with chronic renal failure Felbamate (2-phenyl-1,3-propanediol dicarbamate) is a chemically unique antiepileptic agent which has demon-(Groups 2, 3 and 4) were required to have CL cr values of >30-80 ml min −1 , >10-30 ml min −1 , and >5-10 ml strated efficacy in the treatment of Lennox-Gastaut Syndrome and partial onset seizures [1, 2] . Studies in man indicate that min −1 respectively. All subjects in Group 1 (controls) had no significant medical history, were in good health and were felbamate is well absorbed (>90%), has a volume of distribution of approximately 0.8 l kg −1 , and that binding drug free for at least 2 weeks prior to the study start. Subjects in Groups 2-4 had no other medical conditions to plasma proteins is <25% [3, 4] . Estimates of half-life vary from 14 to 23 h [3] . It is eliminated by both renal than those associated with their chronic renal failure, had stable chronic renal failure, were otherwise in good health, excretion and hepatic metabolism [3, 4] , with the proportion cleared renally being approximately 30% [5] . Felbamate and were maintained on established medication during the study (with the exception of calcium carbonate and metabolites, including 2-hydroxy, parahydroxy and dicarbamate metabolites, are also renally excreted [4] . Because aluminium hydroxide, which were not permitted for 12 h prior to dosing). The reasons for renal dysfunction in felbamate may be used in patients with renal dysfunction, it is important to evaluate the effects of renal impairment on Groups 2-4 included glomerulonephritis (seven subjects), nephrolithiasis with or without pyelonephritis (four subjects), the pharmacokinetics of felbamate. The purpose of this study was to describe the pharmacokinetics of felbamate in and unknown (one subject). All subjects provided written informed consent prior to entry in the study and ethical control subjects and in patients with varying degrees of renal dysfunction.
approval was granted by an Ethics Committee. Volunteers were observed during the study for adverse events, and vital signs and safety laboratory tests were also monitored.
Methods
This was an open label single dose pharmacokinetic study. Following administration of felbamate 1200 mg, pharmacoSixteen adult male volunteers (mean age 45.3 years, range 29-61; mean weight 77.3 kg, range 61-106) participated in kinetic assessment was carried out up to 144 h postdose. Blood samples were collected prior to morning dosing (0 h), this study. They were divided into four groups of four subjects based on creatinine clearance (CL cr ) values obtained and then at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, 16, 24, 36, 48, 60, 72, 96, 120 and 144 h post dose. Twenty-four hour concentrations, which were measured by h.p.l.c.-u.v. (limit of quantification 0.1 mg ml −1 )[4]. Inter-and intra-assay coefficients of variation for felbamate were <14% in both sets of samples. Plasma concentrations were used for pharmacokinetic analyses using model independent methods [6] . The maximum plasma concentrations (C max ) were the observed values. The area under the plasma concentrationtime curve from time zero to 144 h [AUC(0, 144 h)] was calculated using the linear trapezoidal rule. AUC extrapolated to infinity (AUC) was calculated as the sum of AUC to the final measurable sample plus the estimated concentration at the final timepoint (Ct ) divided by the elimination rate constant (l z ). Apparent total body clearance (CL/F ) was calculated from the ratio of dose to AUC, and apparent volume of distribution (V z /F) by the ratio of CL/F to l z . Half-life (t D ) was calculated as 0.693/l z . Renal clearance (CL R ) was calculated as the ratio of the amount of felbamate excreted in the urine from zero to 144 h [Ae(0-144 h)] to plasma AUC(0, 144 h). treatment-related adverse events, including six reports of mild-moderate headache, and single reports of dizziness and dyspepsia. Pharmacokinetic parameters for all four Groups Felbamate CL r was significantly correlated with CL cr (r 2 = 0.75; P<0.001). are summarized in Table 1 , and mean plasma concentrationtime curves are shown in Figure 1 . The small number of subjects in each group precluded formal statistical analysis.
Discussion however the results demonstrate changes in the pharmacokinetics of felbamate in relation to degree of renal function, As might be predicted for a drug which undergoes renal clearance, felbamate's pharmacokinetic profile is altered in as measured by CL cr . Compared with controls, mean concentration-time profiles, C max , AUC and t D values were patients with renal dysfunction. Impaired renal function is associated with higher plasma felbamate concentrations, a greater for subjects with renal dysfunction; CL/F, CL r and Ae(0, 144 h) values were reduced. The only variables which longer half-life, and reduced drug clearance. The reduction in CL r accounts for the progressive decline in CL/F values did not demonstrate progressive changes as renal function diminished relative to controls were nonrenal clearance with diminishing renal function. An unexpected finding is the consistent 30-35% reduction in nonrenal clearance in (CL/F minus CL r ), which was approximately 30-35% lower in subjects with renal dysfunction, and apparent volume of Groups 2-4 relative to the control subjects (Group 1), suggesting that the pharmacokinetic changes observed in distribution, which was approximately 11-17% lower. this study are not only due to changes in the renal We wish to thank Dr Diethard Heimann and Professor Janusz Halushka, Dr Med Lenhard GMBH, Germany for elimination of felbamate. Factors which might contribute to this include changes in the absorption of felbamate, or clinical supervision, and Professor Henning Blume and colleagues at Zentrallaboratorium Deutscher Apotheker, changes in its extrahepatic or hepatic metabolism [7] .
The possibility that the absorption of felbamate is reduced Eschborn, Germany, for expertise in developing and completing the felbamate assays. Dr Pascale Reidenberg and in patients with renal dysfunction cannot be addressed in this study. However some factors which might potentially Mr Jeff Meehan assisted with monitoring and data review, and Mr Scott Fettner assisted with pharmacokinetic analyses. affect absorption can be excluded: for example, no patients reported nausea, vomiting or diarrhoea prior to or following dosing, and phosphate binding agents were withheld for
